SCHEMBL5160340

SCHEMBL5160340

CCc1c(C(=O)NN2CCCCC2)nn(-c2ccc(Cl)cc2Cl)c1-c1ccc(Cl)cc1

nearest known ligand 0.90

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 15/20 0.90
CNR2 P34972 10/20 0.90
CYP2C9 P11712 2/20 0.77
GPR55 Q9Y2T6 2/20 0.77
ABCC4 O15439 1/20 0.77
MLNR O43193 1/20 0.77
ABCB11 O95342 1/20 0.77
CHRM2 P08172 1/20 0.77
ADORA3 P0DMS8 1/20 0.77
ADRA2B P18089 1/20 0.77
ADRA2C P18825 1/20 0.77
DRD1 P21728 1/20 0.77
TBXA2R P21731 1/20 0.77
SLC6A2 P23975 1/20 0.77
HRH2 P25021 1/20 0.77
HTR2A P28223 1/20 0.77
AGTR1 P30556 1/20 0.77
CCKAR P32238 1/20 0.77
CCKBR P32239 1/20 0.77
MC4R P32245 1/20 0.77

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10138900 0.95 CNR1 (0.85) CNR1CNR2CYP2C9GPR55ABCC4
SCHEMBL8226008 0.94 CNR1 (0.84) CNR1CNR2CYP2C9GPR55ABCC4
Surinabant SCHEMBL675894 0.94 CNR1 (1.00) CNR1CNR2CYP2C9GPR55ABCC4
Surinabant SCHEMBL30953789 0.94 CNR1 (1.00) CNR1CNR2CYP2C9GPR55ABCC4
SCHEMBL24238323 0.94 CNR1 (0.82) CNR1CNR2CYP2C9GPR55ABCC4
SCHEMBL30961525 0.94 CNR1 (0.82) CNR1CNR2CYP2C9GPR55ABCC4
SCHEMBL14815936 0.92 CNR1 (0.77) CNR1CNR2CYP2C9GPR55ABCC4
SCHEMBL14155489 0.92 CNR1 (0.80) CNR1CNR2CYP2C9GPR55ABCC4
SCHEMBL7770518 0.91 CNR1 (0.81) CNR1CNR2CYP2C9GPR55ABCC4
SCHEMBL7770528 0.91 CNR1 (0.75) CNR1CNR2CYP2C9GPR55ABCC4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1752149-A1 CB1 Antagonists or inverse agonists as therapeutical agents for the treatment of inflammation involving gene expression LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2007-02-14 EP claimed
EP-1743637-A1 Use of substituted pyrazole compounds and combinations thereof for the treatment of the metabolic syndrome LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2007-01-17 EP claimed
EP-1752149-A1 CB1 Antagonists or inverse agonists as therapeutical agents for the treatment of inflammation involving gene expression LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2007-02-14 EP disclosed
EP-1743637-A1 Use of substituted pyrazole compounds and combinations thereof for the treatment of the metabolic syndrome LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2007-01-17 EP disclosed